Rachana Garg, Ph. D

PDF Department of Pharmacology,School of Medicine, University of Pennsylvania, Philadelphia, USA

Ph.D. Biochemistry (Cancer Biology),Advanced Centre for Treatment, Research and Education in Cancer (ACTREC), Mumbai University, Mumbai

Rachana Garg, Ph. D

Assistant Professor

Tele : +91 7470535946

E-mail : rachanag@niperahm.ac.in, rachana.garg@gmail.com

Research Interest

Elucidating the nature of the dysregulated signaling networks in cancer, as well as association of oncogenic kinases with other common alterations with the ultimate goal of finding novel targeting molecules for cancer therapeutics using varied cellular, biochemical, genetic, and molecular approaches. Another interest is to explore if the identified target molecule has implication a) in the maintenance and stemness traits of oral cancer stem-like cells, b) treatment-resistant recurrence, and c) if its depletion sensitizes cells to chemotherapy.

Experience

  • January 2019 - Present:
    Assistant Professor, NIPER- Ahmedabad, Palaj, Gandhinagar
  • August 2014 – July 2017:
    Research Associate Scientist, University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania, USA.
  • August 2009 – July 2014:Postdoctoral Fellow,University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania, USA.
  • January 2007 – July 2008:
    CSIR-Senior Research Fellow, ACTREC, Cancer Research Institute, University of Mumbai, India.
  • January 2004 – December 2006:
    CSIR-Senior Research Fellow, ACTREC, Cancer Research Institute, University of Mumbai, India.
  • January 2003 – December 2003:
    CSIR-Senior Research Fellow, ACTREC, Cancer Research Institute, University of Mumbai, India.
  • January 2002 – June 2002:
    Research Trainee,Department of Oncology, Institute of Cytology and Preventive Oncology ICPO), New Delhi (now in NOIDA), India.

Honours/Awards/Grants/Consultancies

Honours/Awards

  • Held second rank B.Sc (Botany Honors) in Hindu College, University of Delhi (2002).
  • Graduate Aptitude Test in Engineering (GATE) India (2002).
  • JRF Fellowship Award, Cancer Research Institute, ACTREC, India (2003).
  • CSIR-UGC National Eligibility Test (NET) fellowship, India (2004).
  • Rambhau Kulkarni Award for Best Poster at the 25th Annual Convention of Indian Association of Cancer Research (2006).
  • Best Poster Award at the XXXI Annual Conference of Environmental Mutagen Society of India (2006).
  • Sujata Memorial Award for Best Poster at the International Conference of Society for Free Radical Research Asia (SFRR-ASIA) (2007).
  • Postdoctoral Training Grant Award under the Prostate Cancer Research Program of Department of Defense Congressionally Directed Medical Research Program (DOD-CDMRP), USA (2011).
  • Invited for an oral talk at Scientific Meeting of Philadelphia Prostate Cancer Working Group held at Philadelphia, Pennsylvania, USA (2012).
  • Honored for an oral talk at FASEB Science Research Conferences "Lipid Signaling Pathways in Cancer” held at Steamboats, Colorado, USA (2012).
  • Travel Award from Biomedical Postdoctoral Program Association, University of Pennsylvania, USA (2014).
  • AACR-Aflac, Inc. Scholar-in-Training Award at the Annual Meeting of American Association of Cancer Research, held at Philadelphia, Pennsylvania, USA (2015).

Grants

  • Department of Defence Congressionally Directed Medical Research Program. W81XWH-12-1-0009. Total budget cost: $124,200.PC110483 "PKC Epsilon: A Novel Oncogenic Player in Prostate Cancer”. 08/1/2012–07/31/2014.

Publications

  • Patel, R., Garg, R., Erande S and Maru, G.B. Chemopreventive Herbal Anti-oxidants: Current Status and Future Perspectives. J. Clin. Biochem. Nutr. 40: 82-91 (2007).
  • Garg, R., Gupta, S., and Maru, G.B. Dietary curcumin modulates transcriptional regulator(s) of phase I and phase II enzymes in benzo(a)pyrene-treated mice: mechanism of its anti-initiating action. Carcinogenesis 29: 1022-1032 (2008). (Impact factor: 5.3)
  • Garg, R., Ramchandani, A., and Maru, G.B. Curcumin decreases 12-0-tetradecanoylphorbol-13-acetate-induced protein kinase C translocation to modulate downstream targets in mouse skin. Carcinogenesis 29: 1249-1257 (2008). (Impact factor: 5.3)
  • Garg, R., Ingle, A., and Maru, G.B. Dietary turmeric modulates DMBA-induced p21ras, MAP kinases and AP-1/NF-κB pathway in hamster buccal pouch carcinogenesis. Toxicol. App. Pharmacol. 232: 428-439 (2008). (Impact factor: 3.8)
  • Garg, R., and Maru, G.B. Dietary curcumin enhances benzo(a)pyrene-induced apoptosis resulting in a decrease in BPDE-DNA adducts in mice. J. Environ. Pathol. Toxicol. Oncol., 28: 121-131 (2009).
  • Benavides, F., Blando, J., Perez, C.J., Garg, R., Conti, C.J., DiGiovanni, J., and Kazanietz, M.G. Transgenic overexpression of PKCin the mouse prostate induces preneoplastic lesions. Cell Cycle 10: 268-277 (2011). (Impact factor: 4)Cover of the journal. Also highlighted in News and Views Section: Basu, A. Cell Cycle 10: 378 (2011); and Knudsen, K., Cell Cycle 10: 379 (2011).
  • Garg, R., Blando, J., Perez, C.J., Wang, H., Benavides, F., and Kazanietz, M.G. Activation of Nuclear Factor Kappa B (NF-B) in prostate cancer is mediated by PKCJ. Biol. Chem. 287: 37570-37582 (2012). (Impact factor: 4.1)
  • Garg, R., Caino, M.C., and Kazanietz, M.G. Regulation of transcriptional networks by PKC isozymes: identification of cRel as a key transcription factor for PKC regulated genes. PloS One, 8: e67319 (2013). (Impact factor: 3.3)
  • Garg, R., Benedetti, L., Abera, M., Wang, H., Abba, M., and Kazanietz, M.G. Protein kinase C and cancer: what we know and what we don’t. Oncogene, 33: 5225-5237 (2014). (Impact factor: 8.5)
  • Wang, H., Gutierrez-Uzquiza, A., Garg, R., Barrrio-Real, L., Abera, M., Rosemblit, C., Lu, H and Kazanietz, M.G. Transcriptional regulation of oncogenic Protein Kinase C epsilon (PKC) by STAT1 and SP1. J. Biol. Chem. 289: 19823-19828 (2014). (Impact factor: 4.1)
  • Garg, R.*., Dolas S., and Maru G.B. Dietary curcumin modulates phenobarbital- and acetone-induced CYP450 2B1 and 2E1 isozymes in mice. BAOJ Cancer 1: 005 (2015). * Corresponding author.
  • Barrrio-Real, L., Werthemier, E., Garg, R., Abba, M., and Kazanietz, M.G. Characterization of a PREX1 gene signature in breast cancer cells. Oncotarget 7: 51335-51348 (2016). (Impact factor: 5.2)
  • Garg, R., Blando, J., Perez, C.J., Abba, M., Benavides, F., and Kazanietz, M.G. Protein Kinase C epsilon cooperates with Pten loss for prostate tumorigenesis through the CXCL13-CXCR5 pathway. Cell Reports 19: 375-388 (2017). (Impact factor: 8.3)
  • Cooke, M., Zhou, X., Casado-Medrano, V., Lopez-Haber, C., Baker, M., Garg, R., Lee, J., Blumberg, P and Marcelo Kazanietz. Characterization of AJH-836, a DAG-lactone with selectivity for novel PKC isozymes. J. Biol. Chem. 293: 8330-8341(2018). (Impact factor: 4.1)
  • Garg, R., Lal, P., Blando, J., Benavides, F., Feldman, M. D., Smyth, E. M., and Kazanietz, M.G. COX-2 mediates pro-tumorigenic effects of PKCε in prostate cancer. Oncogene 37:4735-4749. (2018). (Impact factor: 8.5)
  • Garg, R., Abba, M., Feldser, D., Benavides, F., Perez, C.J., and Kazanietz, M.G. Essential role of PKC epsilon in carcinogen-induced and/or KRas-driven lung tumorigenesis. Manuscript in preparation.
Complete list

Book/Book Chapter/Patents/Peer Review Abstract

Books

  • Garg, R.* and Maru, G.B. Evaluation of Mechanism(s) of Turmeric/Curcumin(s) Mediated Chemoprevention and Validation of Biomarkers for Drug Effect Measurements. Lamb. Acad. Pub., Germany, 2016. *Corresponding author.

Books Chapter

  • Maru, G.B., Ramchandani, A., Kumar, G., and Garg, R. Curcumin-mediated cellular responses in chemical carcinogenesis: In vivo studies. Book Chapter: In "Bioactive Foods and Extracts: Cancer Treatment and Prevention” chapter Xth, 181-204 (2010). Ed. Ronald Ross and Vicyor R. Preedy.

Published Abstracts

  • Garg, R., Benavides, F., Blando, J., Wang, H., and Kazanietz, M.G. PKC regulates tumor necrosis factor-induced nuclear factor-B signaling in prostate cancer. Cancer Research 71(8), Suppl. 1; doi:10.1158/1538-7445.AM2011-1031, (2011). (Impact factor: 9.3)
  • Garg, R., Blando, J., Perez, C.J., Benavides, F., and Kazanietz, M.G. PKCcooperates with Pten deficiency in prostate cancer progression. Cancer Research 72 (8 Suppl); doi:10.1158/1538-7445.AM2012-534, (2012). (Impact factor: 9.3)
  • Garg, R., Abera, M. B., Lal, P., Blando, J., Benavides, F., Feldman, M. D., Smyth, E. M., and Kazanietz, M.G. COX-2 as a mediator of oncogenic PKCε in prostate cancer. "Late Breaking Abstract”. Cancer Research 73(8), Suppl. 1; doi:10.1158/1538-7445.AM2013-LB-154 154 (2013). (Impact factor: 9.3)
  • Wertheimer, E., Barrio Real, L., Abba, M.C., Garg, R., Kordon, E., and Kazanietz, M.G. Impacto de P-REX1 sobre la expresión genética inducida por la activación de receptores ERBB en el cáncer de mama y sus consecuencias para la progresión tumoral. (Impact of P-REX1 over the genetic expression induced by the activation of the ERBB receptors in breast cancer and its consequences on tumor progression). Medicina, Vol. 73, Suppl III, 2013, pg 124.
  • Garg, R., Abba M., and Kazanietz, M.G. CXCL13 as a mediator of oncogenic PKCε in prostate cancer. Cancer Research 74 (19 Supplement):1596-1596, doi:10.1158/1538-7445.AM2014-1596 (2014). (Impact factor: 9.3)
  • Garg, R., Blando, J., Perez, C.J., Abba M., Benavides, F., and Kazanietz, M.G. Protein kinase C  cooperates with Pten deficiency to regulate NF-B pathway in prostate cancer progression. Cancer Research 75 (15 Supplement): 799 doi:10.1158/1538-7445.AM2015-799 (2015). (Impact factor: 9.3)
  • Garg, R., Kapur, V., Abba, M., Feldser, D., Albelda, S. and Kazanietz, M.G. PKC epsilon is a mediator of KRAS-driven lung tumorigenesis. Cancer Research 76 (14 supplement) Abstract No. 5164. DOI: 10.1158/1538-7445.AM2016-5164 (2016). (Impact factor: 9.3)
  • Garg, R., Blando, J., Perez, C.J., Abba, M., Benavides, F., and Kazanietz, M.G. Oncogenic PKC epsilon and Pten loss converge on activating CXCL13 via NF-B transcriptional signaling in prostate cancer progression. "Late Breaking Abstract”. Cancer Research 77 (13 Supplement) Abstract No. LB-230. DOI: 10.1158/1538-7445.AM2017-LB-230 (2017). (Impact factor: 9.3)
Presentations:
National : 04
International: 14
Projects:
Completed 01
Go to Navigation